Benzinga | Sep 13, 2021 06:50AM EDT

HC Wainwright & Co. Maintains Buy on Agile Therapeutics, Lowers Price Target to $3.5

HC Wainwright & Co. analyst Oren Livnat maintains Agile Therapeutics (NASDAQ:AGRX) with a Buy and lowers the price target from $7 to $3.5.